ARTICLE | Company News
Dyax submits DX-88 BLA
September 25, 2008 4:50 AM UTC
Dyax (NASDAQ:DYAX) completed submission of a rolling BLA for DX-88 ecallantide to treat hereditary angioedema (HAE). Dyax requested Priority Review for the yeast-derived recombinant plasma kallikrein ...